We are excited to announce that our abstract submission was accepted to be presented at this year's European Conference on Interventional Oncology in Sweden amongst a record 300+ submissions. Additionally, we will be exhibiting our technology at the event amongst Europe's leading clinicians in interventional oncology. Stop by for a chat at our booth to learn more about what the AVAS has to offer.
United States AVAS® Patent - Granted
Today the United States Patent and Trademark Office issued U.S. patent number 11,464,892 to AllVascular which broadly covers the AVAS® device and methods for treating solid tumors. The granting of the AVAS® patent in the U.S. is a significant milestone for the Company and expands on two other patents granted in Australia and New Zealand. For this same patent family, applications are still pending in Brazil, China, Japan, Israel, and Europe. This patent will provide protection for the AVAS® out to 2036. The Company also has international filings for the AVAS® covering future improvements and iterations in a 2020 and 2021 PCT filing which are pending in Australia, New Zealand, United States, Canada, China, India, Israel, Japan, Korea, and Europe.
AllVascular Partners with Boyd Medical to Distribute the AVAS in Turkey, Belgium, Netherlands and France
As we expand our commercialisation effort across Europe and the Middle East, having the right partner is key to success. #Boydmedical is indeed that partner. With Boyd, patients are now being treated in Turkey at Medical Point Izmir with the #AVAS, with further hospitals to open in Istanbul and Ankara. Today, we are excited to announce that we have further partnered with Boyd in the Netherlands, Belgium and France. Together we take pride in providing medical devices and solutions to improve health outcomes for cancer patients.
Welcome to the Medical Advisory Board Dr. Raj
Govindarajan Narayanan, M.D., is a Professor of Radiology at the Herbert Wertheim College of Medicine, Florida International University. He is the Chief of Interventional Oncology at the Miami Cancer Institute, and practices at the Miami Cardiac & Vascular Institute, both part of Baptist Health of South Florida.
Dr. Narayanan’s clinical expertise include trans-arterial and ablative technologies. He is also a pioneer in his field, developing the technique of percutaneous irreversible electroporation (IRE) of the pancreas. His primary clinical research interests include pancreatic, liver and colon cancer. He is widely published in high-impact medical journals and serves as a reviewer and editor for several scientific publications. He has authored text book chapters and is an invited faculty member and speaker at several national and international scientific meetings. Dr.Narayanan is also the Founder and Co-Chair of Spectrum, a multidisciplinary oncology conference held annually in Miami.
AllVascular announces partnership with NSW Health providing $2.4M in non-dilutive capital
AllVascular is pleased to announce that is has been provided with $2.4m from NSW Health to accelerate the commercialisation of its lead product, the AVAS®- Arterial Access System.
The AVAS® has been used in the treatment of patients with unresectable secondary colorectal liver metastases. The results to date have been very promising, with over 60% of patients treated demonstrating clinical benefits. These have included patients that have survived for more than 5 years post treatment, which was well beyond expectations.
AllVascular applied for the funding from NSW Health as part of the Medical Devices Fund(MDF) which is run annually and is designed to encourage and support the development and commercialisation of medical technologies in NSW. Due to the value of the grant the process is competitive and highly sought after. The submissions are reviewed by an expert panel of leading NSW clinicians and experts in commercialisation chaired by Professor Durrant-Whyte (Chief Scientist and Engineer, NSW).
AllVascular is delighted with the support received from NSW Health which provides funding and access to networks facilitated by the Medical Devices Fund Expert Panel and NSW Health.
Presentation at Leading European Interventional Radiology Summit - A/Prof Kevin Ho-Shon
The Company confirms that A/Prof Ho-Shon will be making a presentation to attendees of this years Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Summit to be held online on September 12-15. CIRSE is one of the largest Summits for Interventional Radiology and last year attracted over 7000 delegates in Barcelona, Spain. A/Prof Ho-Shon will be discussing his experience when treating salvage patients using the AVAS® and the 47 patient SYS-CAPLIOX clinical trial.
Presentation at Leading Australian Cancer Conference - A/Prof Nick Pavlakis
The Company confirms that A/Prof Pavlakis will be making a presentation to attendees of this years Australian Gastro-Intestinal Trials Group ASM to be held online on August 28. The subject of this presentation includes an introduction to the Company sponsored clinical study and patient experience with the AVAS® device.
AllVascular Selected by Medtronic to Present at the AusBiotech Talk Series
AllVascular has been shortlisted by MedtronicANZ to present the AVAS® technology at Eureka Live, as apart of the @AusBiotech talk series. In collaboration with AusMedtech 2020, Medtronic Australasia will host Eureka LIVE.
The first event of its kind held in Australia by Medtronic, who are seeking opportunities to bring new technologies to market - either in ANZ or across the globe - in the pursuit of improving community-wide health. Register here: https://bit.ly/2WIYHdz to hear our CEO, David Radford, explain the benefits the AVAS® provides to patients at the event.
BACK TO WORK - Further Patients Implanted With The AVAS®
With COVID-19 restrictions being eased in NSW, AllVascular is pleased to announce that as of last week, further patients have been implanted with the AVAS® to facilitate isolated and direct chemotherapy treatments. AllVascular is supporting the oncology and IR teams to accelerate the treatments for patients with secondary liver cancers.
AVAS® Included on the Australian Register of Therapeutic Goods (ARTG)
AllVascular is pleased to advise that the AVAS® has now been included on the Australian Register of Therapeutic Goods (ARTG). The inclusion now allows the Company to commence the commercialisation of the AVAS® product.
Amanda's Story
Amanda’s Story
In 2014 Amanda Thorne was diagnosed with stage IV bowel cancer which meant she had multiple tumour metastases in her liver. After undergoing 9 rounds of intravenous oxaliplatin chemotherapy the side effects on her body were so severe she was unable to continue treatment. The AVAS® and treatment method enabled her to continue chemotherapy treatment without the side effects. Amanda is now 5 years post treatment with the AVAS®. Hear her story.
AVAS® Arterial Access System Earns CE Mark Approval
AllVascular announces that it has received CE approval for its proprietary Arterial Access System (AVAS®). The AVAS® device enables safe and repeated access to the arterial circulation which can enable the targeted delivery of therapeutic substances (chemotherapy and immunotherapies) to treat solid tumours within multiple organs. This approval enables the Company to commence sales of the AVAS® into European Union (EU) member countries, Hong Kong, Singapore, Australia and New Zealand upon lodgement of the Certificate with the appropriate regulatory authorities.